Equinom
Equinom uses its data advantage and machine learning platform, “Manna”, to predict plant ingredient functionality from genomic data. It is also developing the next generation of non-GMO plant-protein ingredients using computational biology, genomic sequencing and advanced plant-breeding.
"Equinom’s crops double protein yield while cutting processing emissions in half, creating more sustainable and nutrient-rich ingredients for the future of food."
Synthesis has worked closely with Equinom since their Series D round in 2022.
Why we backed them:
Equinom operates squarely at the intersection of foodtech and biotech, combining a unique data advantage with state-of-the-art plant breeding capabilities and a 15+year old proprietary seed library. Its platform offers cleaner, more sustainable, and higher protein plant ingredients, while also unlocking value across the agricultural supply chain through its Manna AI platform.
How Synthesis engaged:
Since our investment in Equinom in 2022, we've maintained a close, hands-on relationship with the team. Recognising the transformative potential of recent advances in AI, we worked together to unlock greater value from Equinom's platform - drawing on more than 15 years of accumulated seed data and the capabilities of their Manna AI platform to drive smarter, faster outcomes across their business.
